Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Partners LLC

Neither a doctor nor a teaching hospital

Research payments

$27,095,477

7,799 payments

Through program year 2025, Clinical Research Partners LLC is reported as receiving $27,095,477 in research payments, across 7,799 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,216,723 537
2024 Research $2,896,581 568
2023 Research $6,470,420 566
2022 Research $6,819,095 4,007
2021 Research $2,988,333 616
2020 Research $1,823,608 817
2019 Research $1,880,717 688

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $7,387,323 408 payments
  2. Moderna TX, Inc. $7,300,165 3,662 payments
  3. AstraZeneca Pharmaceuticals LP $2,888,779 9 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $2,179,719 1,435 payments
  5. Incyte Corporation $1,537,867 447 payments
  6. Novavax Inc $1,024,761 128 payments
  7. AbbVie, Inc. $1,015,164 569 payments
  8. Sanofi US Services Inc. $937,714 105 payments
  9. Janssen Research & Development, LLC $476,543 86 payments
  10. Eli Lilly and Company $307,032 27 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $2,976,979 196 payments
  2. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $2,925,381 44 payments
  3. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $2,878,672 4 payments
  4. A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $2,536,985 56 payments
  5. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $1,815,725 3,248 payments
  6. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,375,162 85 payments
  7. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $1,223,571 136 payments
  8. A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $1,192,492 1,010 payments
  9. A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet $851,282 55 payments
  10. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $827,699 42 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record